Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Uy Ear reaffirmed a Buy rating on Evolus (EOLS) with a $15.00 price target, despite shares closing at $6.18. Ear, a 4-star analyst in the Healthcare sector, maintains this stance. The broader market consensus for Evolus is a Moderate Buy with an average price target of $14.00.
Mizuho Securities analyst Uy Ear reiterated a Buy rating on Evolus yesterday and set a price target of $15.00. The company’s shares closed yesterday at $6.18.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Ear is a 4-star analyst with an average return of 6.9% and a 42.57% success rate. Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Evolus, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evolus with a $14.00 average price target.